Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torcetrapib/Atorvastatin in Familial Dysbetalipoproteinemia
NCT00145431Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of torcetrapib in Familial dysbetalipoproteinemia (FDBL) (3 arms), sponsored by Pfizer. Primary endpoint: Change in LDL-C and non-HDL-C levels. Started Mar 2005; status: terminated.
02
Drugs
torcetrapib
03
Conditions
Familial dysbetalipoproteinemia (FDBL)
Beyond the preview
Go deeper on NCT00145431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00145431.